Doloromics is a precision neuropharmaceuticals company. It was set up four years ago, to use newer technologies, particularly in the omics space, to take advantage of different single-cell transcriptomic technologies or proteomic technologies to better understand the progression of neurological diseases like chronic pain. The Doloromics pipeline is built upon a proprietary discovery and validation platform DOLOReS.  Jackson Brougher, chief scientific officer and co-founder of Doloromics, is our guest on this week’s Beyond Biotech podcast. 00:46-04:41: About Doloromics 04:41-07:09: What is chronic pain? 07:09-08:30: How challenging is the subjectivity of pain? 08:30-11:04: What is nociception? 11:04-12:23: The challenges of treating pain 12:23-16:35: Is chronic pain a disease? 16:35-19:57: What is VX-548? 19:57-22:17: Monoclonal antibodies and CGRPs 22:17-26:22: How have recent advances in genomic technologies advanced the understanding of pain? 26:22-31:03: What is the DOLOReS platform? 31:03-32:37: Delivery methods 32:37-33:55: Keeping costs low 33:55-34:58: Next steps Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!  Stay updated by subscribing to our newsletter